Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Carrie A Strand, Lisa A Kottschade, Rachel A Kudgus, Sarah A Buhrow, Laura R Becher, Liyi Geng, Gretchen E Glaser, Megan E Grudem, Aminah Jatoi, Carolyn M Klampe, Amanika Kumar, Carrie L Langstraat, Robert R McWilliams, Andrea E Wahner Hendrickson, S John Weroha, Yiyi Yan, Joel M Reid, Svetomir N Markovic, Matthew S Block
PURPOSE: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared to sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. PATIENTS AND METHODS: A 3+3 phase I trial was conducted with 3 potential dose levels in patients with previously treated endometrial (EC), cervical (CC), and platinum-resistant ovarian cancer (OC) patients to ascertain the recommended Phase II dose (RP2D)...
March 26, 2024: Clinical Cancer Research